Table 1.

Clinical characteristics of 79 stage IV SQCLC patients

PI3K (n = 33)FGFR1 (n = 16)Other (n = 30)P (PI3K vs. FGFR1)P (PI3K vs. other)P (FGFR1 vs. other)
Age
 Median (range)68 (47–85)73 (48–82)69 (45–87)0.100.360.42
Sex
 Female48%44%30%>0.950.200.52
Smoking history (pack years)
 Median (range)40 (0–90)43 (1–100)27 (0–120)0.630.120.12
 Current or former94%100%80%
 Never6%0%20%>0.950.140.08
KPS
 ≤70%36%38%43%>0.950.790.052
Prior lines of therapy
 Median (range)1 (0–4)2 (0–4)2 (0–4)0.190.0020.15
Treated with platinum doublet
 Proportion (%)21/27 (78%)9/13 (69%)20/25 (80%)0.70>0.950.069
Treated with targeted therapy
 Proportion (%)1/27 (4%)4/13 (31%)00.03
Number of metastatic sites
 >36 (18%)1 (6%)00.400.0250.35

Abbreviation: KPS, Karnofsky performance status.